Raymond James resumed coverage on Dyne Therapeutics with a new price target
$DYN
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $37.00